Diagnosing prediabetes with the Randox Adiponectin Assay
Talking about diabetes can be tough, but it doesn’t have to be.
This month, we’re joining the conversation on diabetes to help raise awareness of the condition, and importantly, how it can be diagnosed, managed, and even prevented.
Today, our focus is on a lesser-known variant of the chronic illness and one which you may not have heard of – prediabetes.
A third of all adults in the UK have prediabetes and with the UK’s estimated 3.8million diabetics estimated to climb to 5million by 2025 – largely as a result of obesity and the ageing population – it’s more important than ever to check if you’re suffering from this pre-cursor to diabetes.
WHAT IS PREDIABETES?
Illness doesn’t just happen overnight. Over time, your body begins to display symptoms but, often, irregularly has been present for some time. Prediabetes is an early indicator of type 2 diabetes which is characterised by the presence of blood glucose levels that are higher than normal but not yet high enough to be classed as diabetes.
For this reason, prediabetes is often described as the “grey area” between normal blood sugar and diabetic levels. In the UK, around 7 million people are estimated to have prediabetes and thus have a high risk for developing type 2 diabetes.
WHAT ARE THE SYMPTOMS OF PREDIABETES?
93% of the 60 million people with prediabetes globally are unaware they have it. This is because the condition often develops gradually without any warning signs or symptoms. In many cases, the sufferer only learns of their diabetic state once the symptoms of type 2 diabetes start to appear.
TESTING FOR PREDIABETES
Traditional biomarker tests used to diagnose type 2 diabetes include Fasting Plasma Glucose, Oral Glucose Tolerance Test, and HbA1c. However, these cannot be utilised as tests for prediabetes, as beta cell damage has already occurred, and insulin insensitivity is already underway.
Adiponectin, a hormone responsible for regulating glucose metabolism has proven to be a strong predictor of type 2 diabetes at a crucial stage – before it has fully manifested.
Adiponectin’s ability to diagnose prediabetes is due to its relationship with a hazardous type of fat within the body which wraps around internal organs. This visceral fat is particularly dangerous because it can occur even within individuals deemed to have a healthy waist circumference, making them appear deceptively healthy simply because they are slim.
By measuring Adiponectin levels, clinicians can identify someone with high levels of visceral fat and therefore at risk of type 2 diabetes long before they would be identified by tests which measure blood sugar levels.
THE BENEFIT OF A PREDIABETES DIAGNOSIS
Whilst being diagnosed with prediabetes may come as a real shock, it offers a unique opportunity for lifestyle modification and prevention that is often not possible with other illnesses.
And this is because prediabetes is reversible. In fact, up to 80% of all cases of type 2 diabetes are preventable – if detected early. We want to help more and more people understand their health as early as possible so they can take reversible action now when there’s the best chance of a positive outcome.
With this information at your disposal, you can then take the necessary action to stop diabetes in its tracks.
For more information about Adiponectin; please visit https://www.randox.com/adiponectin/
To book the world’s most advanced health check which assess up to 350 different indicators of disease at their very earliest stage, including diabetes, visit www.randoxhealth.com
For further information, please contact Randox PR by emailing firstname.lastname@example.org or phoning 028 9442 2413.
The Evidence Evolution is a fully automated immune-analyser with random access. The machine has the capability to process up to 2640 tests per hour with up to 44 analytes screened per biochip. With a wide range test menu Randox can offer the market the service they expect with state-of-the-art intuitive touchscreen software and advanced precision bio-drive robotics.
Metabolic syndrome is described as a combination of diabetes, high blood pressure and obesity. As result of three health conditions going on, it puts the individual at greater risk of developing coronary heart disease, stroke and many other risks. 1 As well as developing additional health conditions it can cause damage to the blood vessels, the blood pressure damages the blood vessels, the obesity causes a lot of strain on the blood vessels and the heart.2 Therefore, can result in serious long-term risks.
Metabolic disease is very common. Studies state that the serious health condition affects about 23% of adults. 3One in four adults in the UK are currently living with metabolic syndrome and often becomes more common with age2.
Usually it affects those who are overweight or considered obese, have an unbalanced diet containing high levels of sugar and fat and have high cholesterol and extremely high blood pressure2 therefore, the condition can be prevented by reducing the risks.
1 According to the NHS, metabolic syndrome occurs when a person has three or more of the following measurements:
- Abdominal obesity (Waist circumference of greater than 40 inches in men, and greater than 35 inches in women)
- Triglyceride level of 150 milligrams per deciliter of blood (mg/dL) or greater
- HDL cholesterol of less than 40 mg/dL in men or less than 50 mg/dL in women
- Systolic blood pressure (top number) of 130 millimeters of mercury (mm Hg) or greater, or diastolic blood pressure (bottom number) of 85 mm Hg or greater
- Fasting glucose of 100 mg/dL or greater
There are many ways to prevent metabolic syndrome from developing, making lifestyle changes for example, ensuring their weight is healthy by increasing physical exercise, eating a well-balanced healthy diet containing whole grains, fruit, vegetables and fish and finally, visiting the GP to monitor and manage blood glucose, blood cholesterol and blood pressure, quit smoking and managing your stress.
Randox offers the Evidence Evolution including two Metabolic Syndrome Arrays which allows multiplex testing from a single sample allowing rapid turnaround time and are suitable for both serum and plasma samples.
Metabolic Syndrome Array I
- Interleukin-6 (IL-6)
- Plasminogen Activator Inhibitor-1 (PAI-1)
- Tumour Necrosis Factor α (TNFα)
Metabolic Syndrome Array II
- C-reactive Protein (CRP)
- Cystatin C
For more information on our Evidence Series or Metabolic Syndrome Range of Assays, contact us at EvidenceSeries@randox.com
This December, treat your friends and family to the greatest gift of all. The gift of health.
Throughout the month, Randox Health are offering a free Specialised Test, Cough, Cold & Flu, with every Everyman or Everywoman Programme purchased.
Examining up to 150 different indicators of health in your body! The programmes are among the most advanced in the world with our Signature Programme being the most advanced, examining up to 350 different indicators of disease and ill-health. This is due to our advanced technology.
The perfect gift, or perhaps Christmas treat for yourself? These 12-month programmes are guaranteed to give you the most advanced picture available of your current health status.
This month, each programme also comes with a free Cough, Cold & Flu check worth £100.
What is the Cough, Cold and Flu check?
In a world where warnings about antibiotic resistance make daily headlines, Randox Health is helping people take back control.
Antibiotics are used to prevent and treat antibiotic infections. But they don’t work for everything. Taking them when we don’t need them can enable dangerous bacteria that lives inside us to become resistant. That means if you need antibiotics in the future, they may not work. As the NHS says, this puts you and your family at serious risk.
Only bacterial infections can be treated with antibiotics, so finding out what’s behind your infection is essential.
With the Randox Health Cough, Cold and Flu test one swab can detect and identify the cause of 21 respiratory infections in just five hours. With this knowledge, you will find out what’s treatment is going to be appropriate for you.
Take the guesswork out of getting better and book your Cough, Cold and Flu test either as a standalone check or for free with or Everyman or Everywoman Programme.
Specialised tests are available at our clinics in London, Liverpool, Holywood and Crumlin, and also through our innovative mobile health clinic. Gift cards can be purchased from as little as £20.
To find out more about the offer or to purchase the most thoughtful of Christmas presents – a gift card for the ‘gift of health’ – please phone our team on 0800 2545 130. You can also drop them an email. email@example.com
Randox Laboratories is this month driving awareness of diabetes and the need for early and accurate diagnosis to enable patients to take preventive action before the condition worsens.
Diabetes UK have stated that diabetes is the fastest growing health threat of our times and an urgent public health issue. Statistics show that since 1996, the number of people living with diabetes has more than doubled. It has been estimated that there are 1.1 million people living with diabetes in the UK that have yet to be diagnosed, including 84,836 people in Northern Ireland.
According to Diabetes UK around 700 people a day are diagnosed with diabetes, which equates to one person every two minutes. If nothing changes, it is estimated that diabetes will affect one in ten people by 2040. This will raise diabetes prevalence from 415 million to 642 million by 2040. With current treatment taking up almost 9% of the annual NHS budget – roughly £8.8bn a year – the implications for future healthcare budgets are clear if this dangerous trend persists.
The good news however, is that recent research has found that type 2 diabetes is preventable through lifestyle changes. The NHS recently released the UK’s National Diabetes Prevention Programme which is aimed at tackling the increasing growing threat of diabetes.
However, following a warning raised by an Oxford University study, which looked into efforts of this Prevention Programme, it was found that it is unlikely to have much impact because the blood tests used were inaccurate at detecting pre-diabetes – the stage at which diabetes is reversible.
The blood tests used in the National Diabetes Prevention Programme were only effective at detecting diabetes at a stage when damage had already been done.
At Randox, we have developed a number of tests that can help detect the earliest possible signs of diabetes, often before symptoms have even manifested – including a pioneering test for the hormone Adiponectin.
Assessing Adiponectin levels allows doctors to calculate a patient’s levels of visceral fat – a dangerous, internal fat stored around organs. This deep fat, which is not visible to the naked eye, is linked to health problems including Type-2 diabetes.
Low levels of adiponectin equate to high levels of visceral fat which can be combated by improving your diet, exercise habits and even stress levels. Given that 70% of Type-2 diabetes can be prevented by lifestyle changes, there is strong correlation that by detecting low levels of Adiponectin and taking corrective and preventive action, it could result in a decrease in the numbers of people who develop the life-altering condition.
In addition to a test for the Adiponectin biomarker, Randox Biosciences have created a Metabolic Syndrome Array that measures 12 markers associated with metabolic syndrome and cardiovascular disease. Metabolic Syndrome is a is a group of cardiovascular risk factors that affects over 20% of adults and results in a person being three times more likely to have a stroke or heart attack, and five times more likely to develop diabetes.
Ultimately, we would like to see all medical professionals who are at the forefront of patient care armed with the most accurate diagnostic tools available. Updating traditional practice may not be easy but we believe it is imperative to do so, if we are to effectively challenge this global epidemic.
Randox remains focused on providing early diagnoses and preventing illnesses by providing innovative diagnostics tests that will continue to revolutionise the healthcare landscape.
For further information, please contact Randox PR by emailing firstname.lastname@example.org or phoning 028 9442 2413.
Do you have a flair for science? Are you an electronic, mechanical or software engineering expert? Or, perhaps, you are a mastermind of manufacturing know-how. There are world-leading careers on offer for world-leading candidates at Randox Teoranta in Dungloe this December.
That’s the message that global diagnostics firm Randox Teoranta wants to send to students, graduates and experienced professionals alike as it opens its doors to the public once again on Monday 24th December 2018.
Held from 9am to 12noon, the morning is an opportunity for those interested in science, engineering, software development and manufacturing roles in Donegal to have a tour of the state-of-the-art facility and chat with Randox Teoranta staff members about the careers on offer.
Randox Teoranta is particularly passionate about attracting back those who have left Ireland to find careers further afield due to lack of opportunities in their particular vocations. Dream careers in science, engineering and manufacturing are available on the doorstep in Dungloe.
Dr. Ciaran Richardson, Head of Research & Development at Randox Teoranta, commented;
“At Randox Teoranta, we’re constantly pushing the boundaries of healthcare and diagnostic capabilities, allowing us to offer world-class career opportunities in the heart of Donegal.
“Our scientists are working on a range of research projects which will lead to quicker diagnoses of conditions such as stroke, gastrointestinal disorders and chronic kidney disease. In 2016, our scientists even developed a pioneering new test to determine a patient’s risk of developing Alzheimer’s disease.
“There are also opportunities for software developers, electronic & embedded systems engineers, validation and mechanical engineers as our technology continues to advance to accommode our scientific breakthroughs.
“Our manufacturing department also boasts a number of competitive roles which are essential to Randox Teoranta’s continuation as a world leader in healthcare diagnostics and associated technology.
“There are fantastic career opportunities here in one of the most beautiful parts of the world – and the quality of life is second-to-none.”
There are a wide variety of career opportunities available at Randox Teoranta. From placement opportunities for college and university students to graduate roles in a variety of fields, young scientists and engineers have the opportunity to get their ‘big break’ on the career ladder with a globally-recognised company.
There are also opportunities for experienced and driven individuals looking for a smart career move. Randox Teoranta offer competitive salaries, career progression, personal development and the opportunity to work in a cutting-edge company paving the way in ground-breaking global health diagnostics.
Healthcare shouldn’t be one-size-fits-all. Neither should your career.
Randox Teoranta’s Open Morning will take place on Monday 24th December 2018 from 9:00 until 12:00 at Randox Teoranta, Meenmore, Dungloe, Co. Donegal.
Students, graduates and experienced professionals are welcome to visit along with their family and friends. Potential candidates are welcome to bring their CV on the day or email it to email@example.com.
Booking is not required, however, more information, including directions, can be found by searching Randox at www.eventbrite.ie.
More information about the open day can also be found by contacting +353 7495 22600 or emailing RandoxPR@randox.com.
Familial Hypercholesterolemia (FH) is a genetic disorder where the child is born with extremely high cholesterol levels. FH can trace back through several generations. Cholesterol is vital for the normal function of the human body therefore, it is important to ensure the cholesterol levels don’t get too high because it can result in early onset cardiovascular disease. 1
The FH Foundation states an interesting fact that 1 in 250 people worldwide have FH and over 90% of these people have not been properly diagnosed 2. Majority of these people won’t know they have FH disease until they have a heart attack!
However, there are no clear symptoms if someone has FH until it is too late and the damage has been done. The warning signs include the following:1
- Swollen tendons/fatty lumps on the knuckles of your hands, at the back of your ankles and knees
- Cholesterol deposits around the eye-lids (looks like pale and yellowish patches)
- Gray-white cholesterol deposits around the corneas
A study in 2008 by the British Heart Foundation found that people with FH who are diagnosed and treated before they develop heart disease live as long people who don’t have FH 4. This theory emphasis the importance of getting early diagnosis to prevent long-term problems. Treatment to prevent cardiovascular disease involves taking medication prescribed by the doctor and making lifestyle changes including; modifying diet, increasing exercise, quit smoking, decrease drinking alcohol and ensure the patient gets regular sleep.
Randox offers the Familial Hypercholesterolemia (FH) Arrays I & II to help encourage early diagnosis with rapid turnaround time allowing results to be reported within days compared to NHS waiting lists which can be substantially longer. The two arrays are rapid, simple and accurate which enables the simultaneous detection of 40 FH-causing mutations (20 mutations per array) within the LDLR, ApoB and PCSK9 genes. The mutational status can be determined rapidly from a single test, with a reduced need for confirmatory testing with NGS. The genetic analysis for FH mutations allows for more accurate diagnosis compared to lipid profiling.
Randox can help using the award-winning Biochip Analyser to achieve early and appropriate treatment for those with FH resulting those to adopt a healthier lifestyle and taking cholesterol-lowering medication, risk of heart disease to live a longer and healthy life!
Familial Hypercholesterolemia (FH) Arrays I & II:
- LDLR – 38 mutations
- APOB – 1 mutation
- PCSK9 – 1 mutation
To find out more about the products that we offer email us firstname.lastname@example.org
The Randox Clinical Laboratories Services (RCLS) team strives to meet the time sensitive, custom-made requirements of research and clinical projects. Accordingly, RCLS is also able to provide support and guidance. They specialise in biomarker and multiplex testing which provide full laboratory services to aid project aims and timelines whilst saving time and money. Currently, there are four laboratories across the UK located in Liverpool, London, Holywood and the Randox Science Park in Antrim.
In 2017 approximately 422,000 diagnoses of STIs were made in England1 and over one million STIs are acquired every day 2.
Sexually transmitted infections (STIs) are a viral or bacterial infection passed from one person to another through unprotected sexual contact.3 Most STIs are curable however, it takes time for the symptoms to appear or show up in tests. Others have no cure, such as HIV, but can be treated to prevent the disease getting worse. Common symptoms of STIs include vaginal discharge, urethral discharge or burning in men, genital ulcers, and abdominal pain 2 although, a person can have an STI without having obvious symptoms of disease.
Randox Clinical Laboratory Services offers a multiplex sexually transmitted infection array allowing you to outsource sample STI testing. It includes common STIs such as Chlamydia, Gonorrhoea, Syphilis, Herpes Simplex I, Herpes Simplex II. The full Multiplex Array can be seen below.
The simultaneous detection is made possible by our award-winning and innovative Biochip Array Technology which utilises multiplex testing methodology in a rapid and accurate format. The type of sample which is sent to our RCLS lab is determined by the visibility of the symptoms. Non-visible symptoms will require a urine sample whereas visible symptoms will require a swab sample.
There are many benefits to outsourcing your STI samples with RCLS, which include the following:
- ISO17025 Accredited Laboratories
- Excellent precision, specificity, sensitivity and accuracy for diagnosis
- Reduced risk of false reporting and a reduced number of unnecessary tests
- Smaller sample volumes are required therefore enabling faster throughput and rapid patient diagnosis
STI Multiplex Array:
- Chlamydia trachomatis
- Neisseria gonorrhoea
- Herpes simplex 1
- Herpes simplex 2
- Treponema pallidum
- Mycoplasma hominis
- Ureaplasma urealticum
- Mycoplasma genitalium
- Haemophilius ducreyi
- Trichomonas vaginalis
If you would like more information on RCLS or our STI testing please contact email@example.com
Randox Toxicology offers the most comprehensive Drugs of Abuse (DoA) test menu across multiple forensic matrices. Our level of expertise in toxicology research and development allows us to adapt quickly to the ever-changing market influences and develop assays for current and novel drugs trends. Excellent assay precision and performance eliminates false reporting, therefore reducing unnecessary confirmatory tests and time lost in the laboratory as a result. Our Biochip Arrays offer CVs typically less than 10%, producing an accurate drug profile to ensure confidence in results.
The Evidence Series of immunoassay analysers are powered by Biochip Array Technology and combine the latest technological advances for drug residue detection using immunoassay principles. The Drugs of Abuse II panel is available for both the Evidence and the Evidence Investigator analysers. The Evidence has a throughput of 90 samples per hour, testing up to 44 tests per sample. The Evidence is a fully automated batch immunoanalyser, allowing for 3960 tests per hour, while the Evidence Investigator is a semi-automated, bench top analyser with testing capabilities of 2376 tests in 70 minutes.
Randox Food Diagnostics recently reported that the European Parliament has banned the use of antibiotics that are important for human medicine use on animals, and is prohibiting any antimicrobials in livestock without a vet prescription. The new legislation, that is to become law by 2022, states that antimicrobials cannot be used to improve performance or compensate for poor animal conditions.
The European Medicines Agency (EMA) have now documented a significant drop in overall veterinary antibiotic sales across Europe. The EMA recognise that the reduction highlights the efforts made by the European Union (EU) and various stakeholders, promoting prudent use of antibiotics in the animal sector and its positive impact. The reduction of antibiotic use in food-producing animals is a key pillar to the EUs One Health Action Plan against Antimicrobial Resistance (AMR), according to a report conducted by the University of Minnesota.
30 countries in total submitted data between 2011 and 2016. German antibiotic sales dropped by 58%. However, whilst the majority of countries saw a drop in sales, six countries reported an increase of more than 5%. Germany’s implementation of an antibiotic minimising programme has helped the country to minimise antibiotic use, by requiring farmers raising cattle, pigs, chickens, or turkeys to report the frequency of antibiotic treatment on their farm every 6 months. If animal treatment frequency is above the median of all farms, operators must evaluate their usage with a veterinarian.
This major step forward in public health has a direct impact on the environment and food. Randox Food Diagnostics recognise the importance of improving the global food safety chain, and continue to transform the landscape by developing high quality revolutionary screening products. Our reliable and economic testing methods enable the user to detect multiple drug and toxin residues from a single sample, including antimicrobials, growth promoting compounds, synthetic steroids, anthelmintics and coccidiostats. With an expanding range of 37 ELISAs, 21 multiplex screening arrays and 20 enzymatic/colourmetric reagents, our trusted solutions ensure that better science means safer food.
For any questions, email us directly at: firstname.lastname@example.org
RTS Reporting Services
At Randox Testing Services we provide a number of reporting options to our customers, including expert witness reports and medical reviews to add clarity and expert examination to results.
Expert Witness Services
An Expert Witness Report is an interpretation of the results of a drug or alcohol test. It provides a detailed explanation of whether or not substances tested for were detected as well as information regarding chain of custody compliance and testing procedures.
As trusted industry experts Randox Testing Services staff are trained to act as Expert Witnesses in legal cases involving drug and alcohol testing. Our experienced team of Reporting Scientists have undergone extensive Expert Witness training to provide professional witness statements or fully written reports for use as evidence in a court of law or industrial tribunals.
Where required a Senior Toxicologist from Randox Testing Services can attend legal proceedings in person to provide expert witness testimony.
Medical Review Services
Our medical review service offers independent and expert examination of positive results under medical confidentiality.
A positive result from a drug and alcohol analysis is a cause for concern. However, there are some cases when there is a legitimate medical reason for the result. Our medical review service allows for the independent and confidential review of the result to determine the cause of a positive result, for example, if an employee is taking prescription medication.
The Medical Review Officer (MRO) assesses a positive result in the light of the donor’s medical background to determine if there is a legitimate medical reason for the result. The MRO helps protect both the rights of the employee being tested and the employer requiring the testing.
Randox Testing Services
At Randox Testing Services we offer customers access to our expertise through providing various reporting options to customers. These reporting services can be utilised in cases where extra clarity or examination is needed to investigate the outcome of a drugs test. These reports are utilised by workplaces as well as those operating within the medico-legal sector.
For more information on our training, education and reporting services, click here.
If you would like to find out more about our drug and alcohol testing programs, contact us today to speak to one of our experience business development executives.
Phone: +44 (0) 28 9445 1011